Mutual Advisors LLC Makes New Investment in ImmunityBio, Inc. (NASDAQ:IBRX)

Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRXFree Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 16,200 shares of the company’s stock, valued at approximately $41,000.

A number of other large investors have also added to or reduced their stakes in the company. Captrust Financial Advisors purchased a new stake in shares of ImmunityBio during the third quarter worth about $41,000. Virtu Financial LLC purchased a new stake in shares of ImmunityBio during the third quarter worth about $51,000. Algert Global LLC purchased a new stake in shares of ImmunityBio during the second quarter worth about $86,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of ImmunityBio during the second quarter worth about $105,000. 8.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on IBRX shares. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. BTIG Research initiated coverage on ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Monday.

View Our Latest Analysis on ImmunityBio

ImmunityBio Stock Up 2.6 %

Shares of NASDAQ IBRX opened at $3.16 on Thursday. The business’s 50 day moving average price is $3.39 and its 200 day moving average price is $4.02. The firm has a market cap of $2.20 billion, a P/E ratio of -3.43 and a beta of 0.86. ImmunityBio, Inc. has a 52 week low of $2.28 and a 52 week high of $10.53.

ImmunityBio Profile

(Free Report)

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

Recommended Stories

Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRXFree Report).

Institutional Ownership by Quarter for ImmunityBio (NASDAQ:IBRX)

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.